BridgeBio Pharma, Inc.
BBIO
$76.08
$1.321.77%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -691.87M | -721.55M | -724.93M | -797.12M | -776.42M |
| Total Depreciation and Amortization | 5.07M | 5.34M | 5.43M | 5.37M | 5.51M |
| Total Amortization of Deferred Charges | 9.71M | 9.22M | 9.02M | 9.64M | 10.52M |
| Total Other Non-Cash Items | 331.06M | 322.68M | 315.63M | 285.03M | 190.52M |
| Change in Net Operating Assets | -88.35M | -59.64M | -51.06M | -87.73M | -85.94M |
| Cash from Operations | -434.37M | -443.95M | -445.91M | -584.82M | -655.81M |
| Capital Expenditure | -1.02M | -1.17M | -1.10M | -1.11M | -778.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | 0.00 | -42.00K |
| Other Investing Activities | -33.72M | -64.46M | -23.39M | -12.26M | 21.21M |
| Cash from Investing | -34.74M | -65.63M | -24.49M | -13.37M | 20.39M |
| Total Debt Issued | 632.50M | 932.50M | 875.00M | 1.38B | 1.38B |
| Total Debt Repaid | -33.08M | -2.01M | -461.01M | -461.01M | -461.01M |
| Issuance of Common Stock | 54.51M | 56.45M | 34.15M | 23.79M | 17.92M |
| Repurchase of Common Stock | -228.80M | -99.02M | -62.50M | -56.48M | -54.89M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -27.08M | -39.06M | -26.35M | -45.90M | -40.01M |
| Cash from Financing | 398.05M | 848.86M | 359.29M | 835.41M | 837.01M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -71.06M | 339.28M | -111.10M | 237.22M | 201.59M |